AI English summary of an SEC filing — figures as filed
ResMed RMDThe company said net revenue for the 3 months ended September 30, 2026 was $1,415 million, up 6% from $1,336 million a year earlier. Diluted earnings per share for the same period were $2.92, compared with $2.37 a year earlier.
Key points
AI summaryThe company said net revenue for the 3 months ended September 30, 2026 was $1,415 million, up 6% from $1,336 million a year earlier. Diluted earnings per share for the same period were $2.92, compared with $2.37 a year earlier.
ResMed said it completed the sale of its MatrixCare business on September 1, 2026 and recognized a divestiture gain of $62 million. Residential Care Software net revenue was $155 million, down 7% from $166 million a year earlier, and the company cited the MatrixCare sale as the reason for the decrease.
The company said its gross margin was 61.5%, compared with 61.2% a year earlier, with research and development expenses of $103 million and selling, general and administrative expenses of $315 million. It cited the Noctrix acquisition costs, employee-related costs and marketing investments, along with $20 million of restructuring and business transformation costs, as factors behind the increase in selling, general and administrative expenses.
ResMed said it entered into an accelerated share repurchase agreement worth $450 million on August 31, 2026 and received an initial delivery of 1.6 million shares. Over the 3 months, operating cash flow was $422 million, cash used in financing activities was $1,278 million, and share repurchases were $936 million.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly Net Revenue $1,415 million, Diluted EPS $2.92
The company said net revenue for the 3 months ended September 30, 2026 was $1,415 million, up 6% from $1,336 million a year earlier. Diluted earnings per share for the same period were $2.92, compared with $2.37 a year earlier.
Source · Based on the MD&A text of the filing
MatrixCare Divestiture Gain $62 million and Residential Care Software Revenue
ResMed said it completed the sale of its MatrixCare business on September 1, 2026 and recognized a divestiture gain of $62 million. Residential Care Software net revenue was $155 million, down 7% from $166 million a year earlier, and the company cited the MatrixCare sale as the reason for the decrease.
Source · Based on the MD&A text of the filing
Gross Margin 61.5% and R&D and SG&A Expenses
The company said its gross margin was 61.5%, compared with 61.2% a year earlier, with research and development expenses of $103 million and selling, general and administrative expenses of $315 million. It cited the Noctrix acquisition costs, employee-related costs and marketing investments, along with $20 million of restructuring and business transformation costs, as factors behind the increase in selling, general and administrative expenses.
Source · Based on the MD&A text of the filing
Accelerated Share Repurchase (ASR) $450 million and Cash Flows
ResMed said it entered into an accelerated share repurchase agreement worth $450 million on August 31, 2026 and received an initial delivery of 1.6 million shares. Over the 3 months, operating cash flow was $422 million, cash used in financing activities was $1,278 million, and share repurchases were $936 million.
Source · Based on the MD&A text of the filing
Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…